Compare SS&C Technologies Holdings Inc. Common Stock (SSNC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SS&C Technologies Holdings Inc. Common Stock vs TG Therapeutics Inc — how do they compare? SS&C Technologies Holdings Inc. Common Stock trades at $82.08 (market cap $19.13B), while TG Therapeutics Inc trades at $54.41 (market cap $8.32B). The key difference: SS&C Technologies Holdings Inc. Common Stock is far larger — about 2.3× TG Therapeutics Inc's market cap, and SS&C Technologies Holdings Inc. Common Stock pays a 1.47% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold SS&C Technologies Holdings Inc. Common Stock for 0 Days and TG Therapeutics Inc for 16 Days on average.
| SSNC | TGTX | |
|---|---|---|
Market Cap | $19.13B | $8.32B |
Volume | 1,333,448 | 1,001,204 |
Sector | Technology | Health |
52-Week High | $89.62 | $59.06 |
52-Week Low | $62.05 | $26.94 |
Typical Hold Time | 0 Days | 16 Days |
Enterprise Value | $26.47B | $8.52B |
Dividend Yield | 1.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
TG Therapeutics trades at $54.34, down 1.68% today, with a bullish technical outlook supported by moving averages. The company shows strong profitability with 55.22% net income margin and 100.28% ROE, though recent quarters saw EPS misses. Revenue guidance for 2026 is raised to $950M for BRIUMVI, with institutional buying interest from major banks. A shareholder investigation by Kuehn Law presents legal overhang.
Outlook remains positive given analyst consensus target of $80.50 (48% upside) and buyout speculation. Key risks include ongoing legal scrutiny and reliance on BRIUMVI's market share growth. The stock offers growth potential but requires monitoring of legal developments and competitive pressures in the MS treatment space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
